Time to Progression of Prostate Cancer on Androgen Deprivation Therapy and Response Correlation with Gleason Score and PSA Value
Advanced Medical Journal · 2026-09-04 · 11 (3) · 287-296
DOI: 10.56056/amj.2026.512 ↗Abstract
Background and Objectives: Prostate cancer progression is influenced by Gleason scores and prostate-specific antigen levels. This study aims to find the association between these markers and the duration until disease progression in patients undergoing androgen deprivation therapy. Methods: This retrospective cohort study included 108 patients with prostate cancer treated at Nanakali Hospital and Rizgary Teaching Hospital in Erbil, Iraq. Data on demographics, clinical variables (prostate-specific antigen levels, the lowest prostate-specific antigen level reached after initiation of androgen deprivation therapy, Gleason score, and time to disease progression), and sites of metastasis were collected. Results: Patients with metastatic disease had higher initial prostate-specific antigen levels (median 102 nanograms per deciliter) compared to non-metastatic patients (median 20.5 nanograms per deciliter, p
EUVIMED